Xeris Biopharma Holdings Inc

For the period ended Dec 31, 2023. Filed Mar 6, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 6, 2024

XERS$15.86+4.3%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Financial Statements Consolidated Balance Sheets as of December 31, 202 and December 31,

Consolidated Balance Sheets

(in thousands, except share and par value)

	December 31, 2023	December 31, 2022
Assets
Current assets:
Cash and cash equivalents	$67,449	$121,966
Short-term investments	5,002	—
Trade accounts receivable, net	39,197	30,830
Inventory	38,838	24,735
Prepaid expenses and other current assets	5,778	9,287
Total current assets	156,264	186,818
Property and equipment, net	5,971	5,516
Operating lease right-of-use assets	23,204	3,992
Goodwill	22,859	22,859
Intangible assets, net	109,764	120,607
Other assets	4,540	4,730
Total assets	$322,602	$344,522
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$11,565	$4,606
Current operating lease liabilities	3,495	1,580
Other accrued liabilities	23,510	36,786
Accrued trade discounts and rebates	22,149	16,818
Accrued returns reserve	14,198	11,173
Current portion of contingent value rights	19,109	—
Other current liabilities	1,167	2,658
Total current liabilities	95,193	73,621
Long-term debt, net of unamortized debt issuance costs	190,932	187,075
Non-current operating lease liabilities	34,764	9,402
Non-current contingent value rights	1,379	25,688
Deferred tax liabilities	2,268	3,518
Other liabilities	4,848	31
Total liabilities	329,384	299,335
Commitments and contingencies (Note 18)
Stockholders’ equity (deficit):
Preferred stock—par value $0.0001, 25,000,000 shares and 25,000,000 shares authorized and no shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	—	—
Common stock—par value $0.0001, 350,000,000 shares and 350,000,000 shares authorized as of December 31, 2023 and December 31, 2022, respectively; 138,130,715 and 136,273,090 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	14	14
Additional paid in capital	610,254	599,966
Accumulated deficit	(617,025)	(554,770)
Accumulated other comprehensive loss	(25)	(23)
Total stockholders’ equity (deficit)	(6,782)	45,187
Total liabilities and stockholders’ equity (deficit)	$322,602	$344,522

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.